Page 215 - 北京京煤集团总医院第十一届·2023学术年会论文集

北京京煤集团总医院 第十一届·2023 学术年会论文集

血管免疫母细胞性淋巴瘤 4 例并文献复习

王秋红，杜桂清，邓桂霞，邵林娟，乔婷婷，聂艳绒(北京京煤集团总医院病理科 102300)

【摘要】目的：提升血管免疫母细胞性淋巴瘤的早期诊断率。方法：本文报道 4 例血管免疫

母细胞性淋巴瘤，通过对 4 例患者临床资料及病理形态的分析，并复习相关文献 26 篇，共
计 650 例，共分析 654 例 AITL 的临床特点及免疫组化特点。结果：本文 4 例患者均为男

性，均大于 60 岁，从发现到诊断分别用时：5 天、5 天、5 天、150 天； 首次就诊到死亡时

间分别是：24 个月、2 个月、19 个月、20 个月。3 例以发热来院就诊发现，1 例以腹股沟淋

巴结肿大来院就诊；均有多发淋巴结肿大及腹水；2 例脾大、1 例肝大。654 例 AITL 患者

中，男性 371 例、女性 283 例；年龄以 60 岁为划分标准的共计 288 例，≥ 60 岁的患者 182

例；乳酸脱氢酶升高者364例；其中174例报道了免疫组化表达情况：CD3阳性 174/174(100%)，

bcl6 阳性 123/144(85.4%)，CXCL13 阳性 93/145（64.1%）、 CD10 阳性 106/172（61.6%）、 Ki-

67 大于 50%占比 92/135(68.1%)。结论：临床针对有多处无痛性淋巴结肿大的大于 60 岁的

患者，要尽快行淋巴结活检病理检查，综合临床特征、病理形态及免疫组化可作出诊断，相

较与淋巴结穿刺，可缩短诊断时间，及时进行干预，避免预后极差的情况。

【关键词】血管免疫母细胞性淋巴瘤；临床特征；病理特征，LDH

Angioimmunoblastic T-cell lymphoma: 4 cases and review of the literature

[Abstract] Objective: to improve the early diagnosis rate of angioimmunoblastic lymphoma.
Methods: four cases of angioimmunoblastic lymphoma were reported. The clinical and

immunohistochemical characteristics of 654 cases of AITL were analyzed by analyzing the clinical

data and pathological morphology of 4 cases and reviewing 26 related literatures. Results: all the 4

patients were male and older than 60 years old. The time from discovery to diagnosis was 5 days, 5

days, 5 days and 150 days respectively; The time from first visit to death was 24 months, 2 months,

19 months and 20 months respectively. 3 cases came to the hospital with fever and 1 case came to

the hospital with enlarged inguinal lymph nodes; There were multiple lymphadenopathy and ascites;

Splenomegaly in 2 cases and hepatomegaly in 1 case. Among 654 patients with AITL, 371 were

male and 283 were female; There were 288 patients whose age was 60 years old, and 182 patients

whose age was greater than or equal to 60 years old; There were 364 cases with elevated lactate

dehydrogenase. Among them, 174 cases reported immunohistochemical expression: CD3 positive

174 / 174 (100%), BCL 6 positive 123 / 144 (85.4%), CXCL13 positive 93 / 145 (64.1%), CD10

- 211 -